Article

Bausch + Lomb expands I/A handpieces line

The latest innovation to Bausch + Lomb's Storz ophthalmic instruments, the silicone CapsuleGuard IA line, has expanded from two to ten single-use instruments and provides cataract surgeons with a wider range of options for both incisions and techniques for irrigation and aspiration.

Chicago-The latest innovation to Bausch + Lomb’s Storz ophthalmic instruments, the silicone CapsuleGuard IA line, has expanded from two to ten single-use instruments and provides cataract surgeons with a wider range of options for both incisions and techniques for irrigation/aspiration (I/A).

The line now offers surgeons the smaller, MICS 1.8 incision option, in addition to the standard 2.2 to 2.8 incision ranges. The single-use, silicone instruments also have three new tip designs, allowing surgeons a wider array of techniques for I/A. The line is compatible with Bausch + Lomb’s Stellaris PC Vision Enhancement System, as well as other ophthalmic surgical platforms.

“Our customers and the patients they serve are at the center of every development we bring to market,” said Cal Roberts, MD, executive vice president and chief medical officer, Bausch + Lomb. “This new offering in our signature Storz line was based on direct feedback from the industry’s surgeons who told us they wanted more choices to better treat their cataract surgery patients.”

The Storz CapsuleGuard IA line of instruments was launched in 2010 and features a smooth silicone exterior surface without exposed metal; a flexible tip for use in the removal of peripheral and subincisional cortical material and capsule polishing; and a soft aspiration port that allows for capsule vacuuming for lens epithelial cell removal. The product line is ideal for lens positioning and post-implant viscoelastic removal.

The Storz CapsuleGuard IA line is available in the United States, Australia, Canada, Europe, Hong Kong, India, and Malaysia.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.